Management of dupilumab-related ocular surface disorders
- PMID: 39229943
- DOI: 10.1093/bjd/ljae350
Management of dupilumab-related ocular surface disorders
Conflict of interest statement
Conflicts of interest A.M.D. is the Deputy Editor of the BJD. A.M.D. has received compensation from the British Journal of Dermatology (reviewer and Editor), American Academy of Dermatology (guidelines writer), Canadian Dermatology Today (manuscript writer), and National Eczema Association (consultant) and Canadian Agency for Drugs and Technologies in Health (consultant). A.M.D. has received research grants to his institution from the National Eczema Association, Eczema Society of Canada, Canadian Dermatology Foundation, Canadian Institutes for Health Research, US National Institutes of Health, and Physicians Services Incorporated Foundation.
Comment on
-
An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024.Br J Dermatol. 2024 Nov 18;191(6):865-885. doi: 10.1093/bjd/ljae344. Br J Dermatol. 2024. PMID: 39236226 Review.
Publication types
LinkOut - more resources
Full Text Sources
